Strong response after fourth dose of mRNA COVID-19 vaccine in autoimmune rheumatic diseases patients with poor response to inactivated vaccine

Imagem de Miniatura
Arquivos
art_AIKAWA_Strong_response_after_fourth_dose_of_mRNA_COVID19_2022.PDF (331.17 KB)
Citações na Scopus
13
Tipo de produção
article
Data de publicação
2022
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
OXFORD UNIV PRESS
Autores
Citação
RHEUMATOLOGY, v.62, n.1, p.480-485, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objectives. To assess immunogenicity of a heterologous fourth dose of an mRNA (BNT162b2) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in autoimmune rheumatic diseases (ARD) patients with poor/non-response to inactivated vaccine (Sinovac-CoronaVac). Methods. A total of 164 ARD patients who were coronavirus disease 2019 (COVID-19) poor/non-responders (negative anti-SARS-CoV-2 S1/S2 IgG and/or neutralizing antibodies-NAb) to the third dose of Sinovac-CoronaVac received an additional heterologous dose of mRNA (BNT162b2) 3 months after last dose. IgG and NAb were evaluated before and after the fourth dose. Results. Significant increases were observed after the fourth dose in IgG (66.4 vs 95.1%, P < 0.001), NAb positivity (5.5 vs 83.5%, P < 0.001) and geometric mean titre (29.5 vs 215.8 AU/ml, P < 0.001), and 28 (17.1%) remained poor/non-responders. Patients with negative IgG after a fourth dose were more frequently under rituximab (P = 0 .001) . Negative NAb was associated with older age (P = 0.015), RA (P = 0 .002) , SSc (P = 0 .026) , LEF (P = 0 .01 6) and rituximab use (P = 0.007) . In multiple logistic regression analysis, prednisone dose >= 7.5 mg/day (OR =0.34; P = 0.047) , LEF (OR =0.32, P = 0.036) and rituximab use (OR =0.19, P = 0.022) were independently associated with negative NAb after the fourth vaccine dose. Conclusions. This is the largest study to provide evidence of a remarkable humoral response after the fourth dose of heterologous mRNA SARS-CoV-2 vaccination in ARD patients with poor/non-response to the third dose of an inactivated vaccine. We further identified that treatment, particularly rituximab and prednisone, impaired antibody response to this additional dose.
Palavras-chave
autoimmune diseases, COVID-19, vaccination, therapy
URI
https://observatorio.fm.usp.br/handle/OPI/53150
Referências
  1. Ahmed S, 2022, ANN RHEUM DIS, V81, P868, DOI 10.1136/annrheumdis-2021-221922
  2. Aikawa NE, 2022, ANN RHEUM DIS, V81, P1036, DOI 10.1136/annrheumdis-2021-222096
  3. Alejo JL, 2021, TRANSPLANTATION, V105, pE280, DOI 10.1097/TP.0000000000003934
  4. Atmar RL, 2022, NEW ENGL J MED, V386, P1046, DOI 10.1056/NEJMoa2116414
  5. Caillard S, 2022, ANN INTERN MED, V175, P455, DOI 10.7326/L21-0598
  6. Connolly CM, 2022, LANCET RHEUMATOL, V4, pE382, DOI 10.1016/S2665-9913(22)00065-0
  7. Curtis JR, 2021, ARTHRITIS RHEUMATOL, V73, pE60, DOI 10.1002/art.41928
  8. Kamar N, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.36030
  9. Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8
  10. Medeiros-Ribeiro AC, 2021, NAT MED, V27, P1744, DOI 10.1038/s41591-021-01469-5
  11. Medeiros-Ribeiro AC, 2022, ANN RHEUM DIS, V81, P710, DOI 10.1136/annrheumdis-2021-221735
  12. Muller RB, 2013, CLIN EXP RHEUMATOL, V31, P723
  13. Araujo CSR, 2022, ANN RHEUM DIS, V81, P889, DOI 10.1136/annrheumdis-2021-221916
  14. Richi P, 2020, CLIN RHEUMATOL, V39, P2751, DOI 10.1007/s10067-020-05042-2
  15. Taylor SC, 2021, J CLIN MICROBIOL, V59, DOI 10.1128/JCM.02438-20
  16. Teles M, 2022, ANN RHEUM DIS, V81, P738, DOI 10.1136/annrheumdis-2021-221641
  17. Yuki EFN, 2022, ARTHRIT CARE RES, V74, P562, DOI 10.1002/acr.24824

Coleções
Artigos e Materiais de Revistas Científicas - FM/Outros
Artigos e Materiais de Revistas Científicas - COVID-19
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - FM/MPE
Artigos e Materiais de Revistas Científicas - FM/MPT
Carregar mais